Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Lymphoma Clinical Trial

Official title:

A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) as Monotherapy, in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3), and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03311412
• Other study ID #: Sym021-01
• Status: Completed
• Phase: Phase 1
• Start date: November 20, 2017
• Est. completion date: March 23, 2022

Study information

• Verified date: May 2023
• Source: Symphogen A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Description:

Part 1 of this study will evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) to establish the maximum tolerated dose (MTD) and/or the selected dose of sequential escalating doses of Sym021 when administered once every 2 weeks (Q2W) by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available

Part 2 of the study will evaluate the safety, tolerability, and DLTs to establish the MTD and/or the selected dose of sequential escalating doses of Sym022 when administered Q2W in combination with a fixed dose of 3 mg/kg of Sym021, each by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available

Part 3 of the study will evaluate of the safety, tolerability, and DLTs to establish the MTD and/or the selected dose of sequential escalating doses of Sym023 when administered Q2W in combination with fixed doses of 3 mg/kg of Sym021 and either 1, 3 or 5 mg/kg of Sym022, each by IV infusion to patient cohorts with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 89
• Est. completion date: March 23, 2022
• Est. primary completion date: March 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients, = 18 years of age at the time of obtaining informed consent.

• Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphoma.

• Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.

• Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.

• Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

• Persons of childbearing potential agreeing to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug(s); men agreeing to refrain from sperm donation during this period.

Exclusion Criteria:

• Women who are pregnant or intending to become pregnant before, during, or within 6 months after the last dose of study drug; women who are breastfeeding; persons of childbearing potential and not willing to use a highly effective method of contraception.

• Central nervous system (CNS) malignancies; patients with known, untreated CNS or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.

• Hematologic malignancies other than lymphoma.

• Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable.

• Active uncontrolled bleeding or a known bleeding diathesis.

• Clinically significant cardiovascular disease or condition.

• Significant ocular disease or condition, including history of an autoimmune or inflammatory disorder.

• Significant pulmonary disease or condition.

• Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.

• An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive medications.

• History of organ transplantation (e.g., stem cell or solid organ transplant).

• History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy.

• Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy except for persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, lymphopenia, hypomagnesemia, and/or end-organ failure being adequately managed by hormone replacement therapy.

• Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.

• Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).

Drugs and Other Treatments Exclusion Criteria:

• Part 2 Combination Dose-Escalations ONLY: Prior therapy with:

• Sym021 or other inhibitors of PD-1/PD-L1.

• Sym022 or other inhibitors of LAG-3, if participating in Arm A.

• Sym023 or other inhibitors of TIM-3, if participating in Arm B.

• Part 3 Combination Dose-Escalations ONLY: Prior therapy with:

• Sym022 or other inhibitors of LAG-3

• Sym023 or other inhibitors of TIM-3

• Any antineoplastic agent for the primary malignancy (standard or investigational) within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to first study drug administration and during study, with exceptions.

• Any other investigational treatments within 2 weeks prior to and during study; includes participation in any medical device or supportive care therapeutic intervention trials.

• Radiotherapy, with exceptions.

• Use of live vaccines against infectious diseases 4 weeks prior to first study drug administration and during study.

• Immunosuppressive or systemic hormonal therapy within 2 weeks prior to first study drug administration and during study, with exceptions.

• Prophylactic use of hematopoietic growth factors within 1 week prior to first study drug administration and during Cycle 1 of study.

Related Conditions & MeSH terms

• Lymphoma
• Metastatic Cancer
• Solid Tumor

Intervention

Drug:
• Sym021
Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
• Sym022
Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
• Sym023
Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
United States	South Texas Accelerated Research Therapeutics (START) Midwest	Grand Rapids	Michigan
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	NEXT Oncology	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Symphogen A/S

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.	Assess the safety and tolerability of Sym021 monotherapy on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.	12 months
Primary	Part 2: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.	Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 or Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.	12 months
Primary	Part 3: Assessment of treatment emergent adverse events (AEs) meeting DLT criteria.	Assess the safety and tolerability of the Sym021 RP2D in combination with sequential escalating doses of Sym022 and Sym023 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1.	12 months
Secondary	Evaluation of the immunogenicity of Sym021 as a single agent and in combination with Sym022 and Sym023.	Serum sampling to assess the potential for anti-drug antibody (ADA) formation.	24 months
Secondary	Evaluation of objective response (OR) or stable disease (SD).	Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017), or Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST), depending on tumor type.	24 months
Secondary	Time to progression (TTP) of disease.	Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type.	24 months
Secondary	Area under the concentration-time curve in a dosing interval (AUC)	Will be estimated using non-compartmental methods and actual timepoints.	24 months
Secondary	Maximum concentration (Cmax)	Will be derived from observed data.	24 months
Secondary	Time to reach maximum concentration (Tmax)	Will be derived from observed data.	24 months
Secondary	Trough concentration (Ctrough)	Will be derived from observed data.	24 months
Secondary	Terminal elimination half-life (T½)	Will be estimated using non-compartmental methods and actual timepoints.	24 months
Secondary	Clearance (CL)	Will be estimated using non-compartmental methods and actual timepoints.	24 months